Dr Hilary Cass, who authored the Cass report on gender medicine for children, has publicly defended a proposed clinical trial examining puberty blockers, arguing that the research is necessary to protect young people from harm.
The Case for Proceeding
Dr Cass has positioned the trial not as an expansion of risk but as a means of reducing it. Her central argument is that withholding structured, evidence-generating research leaves children in a more precarious position than conducting the trial under controlled conditions.
absolutely convinced that more children will be harmed if we don't do the trial than if we do
That position reflects a broader concern about the consequences of inaction in an area where the evidence base has been widely debated among clinicians and researchers.
Context of the Cass Report
The Cass report examined gender medicine as it applies to children and has been a significant reference point in ongoing discussions about how puberty blockers are used and studied. Dr Cass's involvement in advocating for the trial underscores the report's continued relevance to clinical policy discussions.
The proposed trial represents an attempt to generate more rigorous data on puberty blockers, a class of medications that suppress the hormonal changes associated with puberty. Their use in gender-related care for children has been the subject of considerable scientific and ethical debate in multiple countries.
Harm Reduction as a Framework
Dr Cass's framing centres on harm reduction rather than ideological positioning. By characterising the absence of a trial as itself a source of potential harm, she challenges the assumption that caution necessarily means avoiding research. In her view, the lack of high-quality evidence is itself a clinical problem with real consequences for children and the clinicians treating them.
The argument draws attention to a tension that runs through many areas of paediatric medicine: when evidence is limited, decisions must still be made, and those decisions carry their own risks regardless of which direction they take.
The proposed trial has not yet been described in full public detail, and questions about its structure and scope remain subjects of ongoing discussion among researchers and policymakers involved in gender medicine.